Episodios
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Unfriendly Neighbors: Cardiorenal Syndrome and Heart Failure”, presented by Dr. Graham Wong, we will review the recommendations from the management of patients with heart failure and cardiorenal syndrome (CRS), based on the 2021 CCS/CHFS Heart Failure Guidelines Update. Practical information will be shared on monitoring electrolytes and creatinine, managing loop diuretics, and addressing persistence volume overload and diuretic resistance. An on-demand version of the 30-minute episode presented by Dr. Jonathan Howlett on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “I Dissent: What Works with Non-compliant patients”, presented by Dr. Sabe De, you will learn best practices for the management of patients who have difficulty complying with their heart failure treatment. I’ll share with you practical and concise information that you can apply in your practice today. An on-demand version of the 30-minute episode presented on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode! This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
¿Faltan episodios?
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Recommendations for Initiation of SGLT2i in Patients with HF and T2D” presented by Dr. Grace Chua, we will focus on the initiation of SGLT2i in patients with HFrEF and Type 2 Diabetes and we will review practical tips and key questions to a patient case. An on-demand version of the 30-minute episode presented on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!
This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Newly Diagnosed HF: Initiation of GDMT”, presented by Dr. Graham Wong, you will learn which drug to start first, whether there is a preferred sequence to start with, whether one drug should be fully titrated before starting the next one, what to do if the patient has hypotension and Heart Failure and more! An on-demand version of the 30-minute episode presented on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!
This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Is there a right or a wrong way? Sequencing of foundational therapy in HFrEF” presented by Dr. Lisa Mielniczuk, you will learn which drug to start with, whether there is a preferred sequencing to start with, how many drugs can be initiated at once, and how they should be titrated. An on-demand version of the 30-minute episode presented on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!
This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Is It time for device implantation yet?” presented by Dr. Ryan Davey, you will learn how to recognize when your patient with heart failure should be referred to CRT or ICD implantation, what do the 2021 CCS/CHFS Guidelines Update recommend in terms of device types and timing of implantation and how to evaluate the risks and benefits for individual patients. An on-demand version of the 30-minute episode presented on the same topic is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!
This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS) entitled “Beyond Foundational Therapy: When to Reach in the Tool Box” presented by Dr. Lisa Mielniczuk, we will discuss the clinical characteristics that warrant the initiation of additional treatments beyond foundational therapy and help you identify patients who experience worsening heart failure. An on-demand version of the 30-minute episode on the same topic presented by Dr. Shelley Zieroth is available right now at www.imedicus.ca/hf21. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca. We hope you enjoy this episode!
This program was made possible through grants from Novartis and BI-Lilly Alliance.
-
In this episode presented by the Canadian Heart Failure Society (CHFS), we are joined by Dr. Anique Ducharme, President of the CHFS and Director of the Heart Failure Clinic at the Montreal Heart Institute, and Dr. Shelley Zieroth, cardiologist at St. Boniface Hospital in Winnipeg. They discuss some of the challenges as well as evidence-based recommendations for the management of hyperkalemia and chronic kidney disease in patients with heart failure. An on-demand version of the 60-minute webinar presented on the same topic is available right now at www.iMedicus.ca/Top3. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca.
This program was made possible through educational grants from Bayer Inc. and Otsuka Pharmaceutical.
-
In this episode presented by the Canadian Heart Failure Society (CHFS), we are joined by Dr. Anique Ducharme, President of the CHFS and Director of the Heart Failure Clinic at the Montreal Heart Institute, and Dr. Justin Ezekowitz, co-Director of the Canadian VIGOUR Centre and cardiologist at the Mazankowski Alberta Heart Institute in Edmonton. They discuss some of the challenges as well as evidence-based recommendations to improve outcomes in patients with worsening heart failure. An on-demand version of the 60-minute webinar presented on the same topic is available right now at www.iMedicus.ca/Top3. To learn more about the Canadian Heart Failure Society and find out more about upcoming programs and initiatives, visit www.heartfailure.ca.
This program was made possible through educational grants from Bayer Inc. and Otsuka Pharmaceutical.
-
In this episode, Dr. Stephanie Poon, Cardiologist at Sunnybrook Health Sciences Centre and Medical Co-Director of the Heart Function and Rapid Cardiology Assessment Clinic, and Dr. Katie Connolly, Cardiologist at St Joseph’s Healthcare Hamilton and Hamilton Health Sciences Center discuss how implementing the new CHFS Order Set in your hospital can improve outcomes for patients with heart failure. They discuss the impetus for the development and implementation of the CHFS Order Set, some of its key components as well as the evidence that shows that the use of a heart failure Order Set helps improve outcomes.
Improved Heart Failure Outcomes Begin with Updated Order Sets. To download the CHFS Order Set and implement it in your hospital today, visit https://hfordersets.ca/
For more information and resources, visit the Canadian Heart Failure Website at www.heartfailure.ca
This program is made possible through funding from Novartis Canada.
-
In this episode, Dr. Stephanie Poon, Cardiologist at Sunnybrook Health Sciences Centre and Medical Co-Director of the Heart Function and Rapid Cardiology Assessment Clinic, and Dr. Sean Virani, Cardiologist at Providence Health Care and St. Paul’s Hospital, and Co-Chair of the 2021 CCS/CHFS Heart Failure Guidelines, discuss the current state of heart failure care in Canada. Dr. Poon talks about some of the findings from the Canadian Cardiovascular Society National Quality Project. They discuss quality indicators such as the 30-day readmission rate, length of stay and timing of hospital discharge, and whether there have been some changes over the last decade. Dr. Virani talks about the CAN-HF Registry which looks at patients who are hospitalized as well as patients in the ambulatory visits to see if they are treated as per guideline-directed medical therapy and the impact on patient outcomes.
For more information and resources, visit the Canadian Heart Failure Website at www.heartfailure.ca
This program is made possible through funding from Novartis Canada.
-
In this episode, Dr. James Januzzi, Hutter Family Professor of Medicine at Harvard Medical School and cardiologist at the Massachusetts General Hospital in Boston, discusses with Dr. Shelley Zieroth, Cardiologist at St. Boniface Hospital in Winnipeg, Manitoba and the Immediate Past President of the Canadian Heart Failure Society. Dr. Zieroth and Dr. Januzzi discuss the 2021 updates to the ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment as well as the 2021 CCS/CHFS Heart Failure Guidelines Update. They discuss emerging evidence that support the treatment of HFrEF with 4 standard therapies: ARNI, Beta Blocker, MRA and SGLT2is. They end their conversation with an important message on the way healthcare professionals can advise their patients on how these comprehensive therapies can help them live longer and improve their quality of life.
For more information and resources, visit the Canadian Heart Failure Website at www.heartfailure.ca
This program is made possible through funding from Novartis Canada.
